 Introducing an efficient viral delivery technique for optogenetics in NHP  Convection-enhanced delivery (CED) of virus leads to high levels of expression  Wide-spread optogenetic expression across cortical areas following thalamic CED  Expression is limited to specific areas due to thalmo-cortico-thalamic projections  Reliable light-evoked activity from single cells in cortex following thalamic CED ABSTRACT Background: In non-human primate (NHP) optogenetics, infecting large cortical areas with viral
INTRODUCTION
Optogenetics has great potential to enhance our understanding of neural computation, cognition and behavior. It gives the experimenter control of the activity of specific group of cells with precise timing , enabling the investigation of the causal role of neural circuits in behavior.
Optogenetics has been successfully used in non-human primates (NHP) in recent years (Diester et al., 2011 , Gerits et al., 2012 , Jazayeri et al., 2012 , Ohayon et al., 2013 , Ruiz et al., 2013 , Dai et al., 2014 , Afraz et al., 2015 . However, to take full advantage of the great potential of optogenetics, there are challenges that we still need to overcome.
One major difficulty of applying optogenetics in NHPs is to transduce large regions of brain with high and uniform levels of expression. Recently, we demonstrated that MR-guided convection enhanced delivery (CED) transduced large areas of cortex by infusing the virus in the primary somatosensory (S1) and motor (M1) cortices (Yazdan-Shahmorad et al., 2016) . CED has proven to be an effective technique to deliver large molecules to the central nervous system in gene therapy applications (Bankiewicz et al., 2000 , Krauze et al., 2005 , Kells et al., 2009 . With CED, relatively large volumes are infused into the parenchyma to create pressure that drives bulk fluid flow (convection), achieving wider and more evenly distributed infection in the target tissue. When performing CED infusions in the cortex, we were able to achieve large areas of transduction (>1.1 cm 2 , with less than 5 injections).
However, for many applications, it would be ideal to have expressed optogenetic channels over larger regions of the brain without trauma associated with placement of infusion cannula in the cortex, for example to study cortical connectivity between areas.
Bankiewicz Lab has previously been shown that CED infusions of AAV2 vector into NHP thalamus result in an efficient transduction of thalamocortical neurons, leading to widespread expression of the transgene in the cortex through axonal transport (Kells et al., 2009 ). The reciprocal thalamo-corticothalamic loop and the topospecific connections between thalamus and cortex provide strong circuits to propagate viral vectors to large cortical areas. We therefore expected that a large thalamic transduction with viral vectors carrying light-gated ion channels would result in the expression of these transgenes in wide cortical areas. In particular achieving expression only in the cortico-thalamocortical neurons would provide a very powerful tool to study these pathways in association with behavior in NHPS.
To verify this, we performed bilateral CED infusions of AAV optogenetic viruses into the thalamus of three NHPs. Acute electrophysiological experiments were carried out weeks later, allowing time for light-gated ion channels to express. During these experiments, we performed direct surface illumination of the cortex to observe the cortical infection distribution of YFP in vivo; and we performed single cell recording in response to local optically stimulate. Lastly, histological analysis was used to assess the distribution of expression across cortex.
MATERIALS AND METHODS
Two female and one male rhesus macaques (NHP-A: 9 years old, 7.5 kg; NHP-B: 11 years old, 6.5 kg; NHP-H: 8 years old, 8.7 kg) were included in this study. All procedures were performed under the approval of the University of California, San Francisco Institutional Animal Care and Use Committee and were compliant with the Guide for the Care and Use of Laboratory Animals.
AAV Vectors
Four different AAV vectors with CamKIIa promoter and ChR2 opsin (AAV2.2-CamKII-ChR2(H134R)-YFP, titer: 1.02×10
13 virus molecules/ml; AAV2.5-CamKII-ChR2(H134R)-mCherry, titer: 5.79×10 12 virus molecules/ml; AAV2.9-CamKII-ChR2(H134R)-mCherry, titer: 2.35×10 12 virus molecules/ml and AAV2.9-CamKII-ChR2(H134R)-YFP, titer: 5.26×10 12 virus molecules/ml) were injected to either left or right thalamus. All four vectors were obtained through custom order from the University of Pennsylvania Virus Vector Core facility with plasmids obtained from Addgene plasmid repository (Addgene plasmid codes: #26969, #26975, #26975, #26969, respectively). However for viruses with the mCherry fluorescent reporter, we did not see levels of expression comparable to those observed with the YFP reporter, using either anatomical or physiological measures. Immunostaning also showed very weak expression for these vectors, and therefore they are not considered in the rest of the manuscript.
Real-time MR-guided convection enhanced delivery.
Cannula array implantation: All parenchymal infusions in NHP brains were performed by MR-guided CED as previously described (Bankiewicz et al., 2000 , Krauze et al., 2005 , Krauze et al., 2008 , Kells et al., 2009 , Yazdan-Shahmorad et al., 2016 . Briefly, under isoflurane anesthesia, the animal's head was placed in an MRI-compatible stereotactic frame (KOPF, 1430 MRI) and T1 and T2 anatomical MR images were performed as baseline reference. Baseline images were used to determine the optimal implant location and trajectory for targeting the thalamus. Vital signs, including heart rate and pO2, were monitored throughout the procedure. Two circular craniotomies (1.5 cm diameter) centered on the pre-planned trajectories were performed at each hemisphere with ~20° angle from the vertical in order to avoid the lateral ventricle. Two cylindrical custom-made CED cannula arrays were skullmounted in each craniotomy to provide cannula support during CED infusion ( Figure 1A ). All the implants were secured to the skull using plastic screws and dental acrylic.
Parenchymal delivery: Two weeks after array implant the MR-guided infusion was performed. Briefly, the infusion system consisted of a custom-designed, fused silica, ceramic/fused silica, reflux-resistant cannula (MRI Interventions, Irvine CA) with a 3-mm stepped tip ( Figure 1B ) connected to a loading line (containing the virus solution) and a micro-infusion pump (Harvard PHD 2000, Harvard apparatus, Holliston, MA, USA). Anatomical MR images were obtained and used to select the cannula-guide array location and insertion depth needed to reach the target infusion site. The cannula was manually inserted through the cannula-guide array to the target depth. A T1 MRI contrast agent, gadoteridol (2mM Gadoteridol, Prohance, Bracco Diagnostics, Princeton, NJ) was co-infused with the viral vector
(1:250) and flash T1 images were taken sequentially during the infusion. We infused ~10uL of vector and then obtained an MR image in order to verify correct cannula placement. The cannula was then secured and infusion was performed with infusion rates between 0.5 μl /min and 3 μl/min ( Figure 1C ).
Animals received infusions either in the anterior and posterior thalami (AT+PT: NHP-A and NHP-B) or only in medial thalamus (MT: NHP-H) with a volume range between 85 and 246 μl total per site (see Table 1 ). After the infusion, the cannula was slowly removed from the brain and the cannula arrays were explanted.
Acute Physiology Experiment
Four to twelve weeks post infusion we performed acute physiological experiments to estimate the extent of viral expression via epifluorescent imaging and to attempt recording light-evoked responses.
To these ends, we made a 4 cm ×12 cm craniotomy over sensorimotor cortex in each hemisphere.
The craniotomies were made at the level of the superior pre-central dimple (SPCD) and superior postcentral dimple (SU), centered on the central sulcus (CS), and spanning--along the sagittal axis-from the superior limb of the arcuate sulcus (SAR), directly dorsal from the spur (ARSP), to the intraparietal sulcus (IPS).
Epifluorescence imaging: To confirm YFP transgene transduction, epifluorescence imaging of the cortical surface was performed, as previously described (Diester et al., 2011 , Yazdan-Shahmorad et al., 2016 . Briefly, we manually scanned the surface of the brain with blue laser light (488nm, 20mW
power at the tip; PhoxX 488-60, Omicron-Laserage, Germany) using an optical fiber (core/cladding diameter: 62.5/125µm, Fiber Systems, Allen, TX, USA) placed approximately 5 cm from the cortical surface. Images were captured at 24 frames/sec with a 180-532 nm emission filter (OD: 8+, T5E07, Laservision, St. Paul, USA), using a video camera (JVC GZ-HM550BU camcorder) attached to a surgical microscope (EMZ-8TR, Meiji Techno, Japan). We then scanned the surface in an approximate raster pattern, and image intensity was averaged across frames to estimate the expression areas.
Electrophysiology with Optical Stimulation: Custom-made optrodes (Gradinaru et al., 2007 , Diester et al., 2011 were used for light stimulation and electrophysiological recordings (Tucker-Davis Technologies system). These consisted of a fiber optic cable (core/cladding diameter: 62.5/125 µm, Fiber Systems, Allen, TX, USA) glued to a tungsten electrode. The optrode was mounted on a stereotaxic arm, to facilitate accurate position and depth of the recording. The optrode was used to record neural signals optically stimulating with constant illumination over intervals of 250-500 ms.
The procedure was performed at multiple cortical sites on a pre-establish grid with 5 mm spacing along the anterior-posterior and medial-lateral axes. Prior to these recordings, isoflurane was gradually withdrawn and pentobarbital was administered intravenously until the animal was stabilized.
Supplemental doses of pentobarbital were administered throughout the experiment as needed to maintain a stable level of anesthesia.
Immunohistochemistry
At the end of the acute experiments, animals were deeply sedated and transcardially perfused with heparinized phosphate buffered saline (PBS) followed by ice-cold 4% paraformaldehyde in PBS.
Brains were harvested, post-fixed by immersion in 4% paraformaldehyde/PBS for 24 hours at 4 o C, and then sliced into 6-mm coronal blocks using a custom matrix. After incubation in 30% sucrose, blocks were frozen and cut on a cryostat into 50μm-thick sections, collected in cryoprotectant and stored at -20 o C. Evenly spaced representative sections were selected from each block and processed for YFP immunocytochemistry using a free-floating technique. For immunoperoxidase staining, sections were initially washed in PBS, incubated in 3% hydrogen peroxide/PBS for 10 min to quench endogenous peroxidase activity, then rinsed in two changes of 50% ethanol followed by three changes of PBS for 5 min each. Next we incubated the sections in 5% normal donkey serum in PBS for 1 hour to block non-specific binding. Primary rabbit polyclonal anti-YFP antibody (Abcam, RRID: AB_303395) was diluted 1:15,000 in PBS containing 0.01% Triton X-100 and was applied to the tissue for 48 hours at 4 o C. Sections were then rinsed in PBS, incubated in biotinylated donkey antirabbit antibody, (1:2,000, Jackson Immunoresearch) for 12 hours at 4 o C, rinsed and incubated in ExtrAvidin (Sigma-Aldrich, 1:5,000) for 5-6 hours in room temperature. Peroxidase was detected using a diaminobenzidine chromogenic reagent (Sigma-Aldrich). Sections were rinsed in PBS, mounted on gelatin-coated slides, air-dried, dehydrated in graded alcohols, cleared in xylene and coverslipped with D.P.X. mounting media (Sigma-Aldrich). Consecutive sections were stained against NeuN (1:300; MAB377 Millipore) and MHC-II (1:300; M3887-30 US Biological) to evaluate any possible inflammatory process as previously described when a foreign protein is expressed in the brain (Ciesielska et al., 2013 , Samaranch et al., 2014 .
To assess the distribution of ChR2-YFP-expressing cells across cortical layers, we performed double immuofluorescence for YFP and neurofilament (NF), is a layer-specific pyramidal cell marker.
The NF stain was accomplished with mouse monoclonal antibody against heavy molecular weight non-phosphorylated neurofilament (SMI-32R, 1:5,000; BioLegend; (Hof et al., 1995) ). Secondary donkey anti-mouse Alexa 594 conjugated and donkey anti-rabbit Alexa 488 antibodies (both 1:250, Jackson Immunoresearch) were applied to visualize antigens. Double immunofluorescence for YFP and parvalbumin (monoclonal, 1:1000, Sigma-Aldrich) was also performed in order to analyze transgene expression in the reticular thalamic nucleus. Sections for immunofluorescence microscopy were mounted on gelatinized slides and coverslipped using Vectashield mounting media. Imaging was performed with a Nikon 90i microscope equipped with a color CCD camera and an LSM510 META confocal microscope (Zeiss Microsystems).
Data analysis
We estimated the spread of the viral vector infusion by analyzing the T1 weighted MR images using 
RESULTS

Convection Enhanced Delivery (CED) under MRI Guidance
We performed CED thalamic infusions under guidance of real-time MR images, allowing us to monitor the spread of the vector during the course of the infusion ( Figure 1C ; see Methods). We estimated the three-dimensional (3D) distribution volumes in a post-hoc analyses of the MR images ( Figure 1D ), confirming coverage of the thalamus. This distribution is consistent with previous reports using the same reflux-resistant cannula (Krauze et al., 2005) .
The total injected amount of the material was similar for all animals, as was the total distribution volume inferred from real-time MR images (Tables 1). The ratio of distribution to injection volume was largest for the NHP-H-the one animal that received only a single infusion in MT. This indicates that a single MT infusion was at least as efficient-if not more so-than two smaller infusions in AP and PT.
Histological Analysis
Histological analyses of serial coronal sections revealed high levels of YFP expression throughout the injected thalamus, large areas of the cerebral cortex and many subcortical structures described below (Figures 2 and 3, Table 2 ).
Thalamic YFP expression:
We observed similar patterns of thalamic YFP expression across the three animals that matched the MRI distribution (Figure 3) . YFP-positive cell bodies and neuropil were present in most of the anterior and mid-thalamic tissue (Figures 2 and 3, Table 2 ).
In all animals, YFP expression extended anteriorly and laterally to the internal capsule. Expression was also observed in the striatum, with strong expression in the dorsal caudal nucleus (Cd) (Figure 2 ).
The most lateral YFP-positive thalamic cells were in the reticular nucleus (Rt) (Figure 2 ).
Unexpectedly, since the vectors carried a CAMKII promoter, transgene expression was observed in YFP staining also extended to medial thalamic nuclei such as mediodorsal thalamus (MD), and even into the contralateral thalamus. Contralateral spread was verified in NHP-A, where a YFP vector was infused unilaterally in AT and PT ( Figure S2A ). A similar, but weaker, contralateral spread was seen in NHP-H, which also received a unilateral MT infusion. This spread could be due to contralateral axonal transport from the medial nuclei, and the difference may be due to the fact that the medial nuclei were not as strongly labeled in NHP-H compared to NHP-A and NHP-B (compare NHP-H in Figure 4A to NHP-B in Figure 2A and NHP-A in Figure S2A In NHP-H, we also observed this spread involved all of MGN and parts of the parvocellular layers 6 and 5 of the LGN ( Figure 5A ,B arrow). NHP-A and NHP-B had little or no YFP expression in MGN or LGN (Figure 2A ).
In particular, the posterior and ventral spread of YFP staining was greater for the MT infusion (NHP-H), as compared to NHP-A and NHP-B. The posterior and ventral spread of YFP expression also went beyond the thalamus, involving hypothalamus, medial mammillary nucleus, red nucleus, and subthalamic nucleus (Figure 2 , 4, 5, Table 2 ), also reaching mesencephalic areas such as tectum, parts of substantia nigra and ventral tegmental area, reticular formation, pontine nuclei and pons (table 2, Figure 5A , B).
Cortical expression: Cortical YFP expression closely corresponded to the known distribution of thalamocortical axons and corticothalamic neurons in all animals as shown below. Expression was observed throughout most of the frontal and parietal cortices, and in parts of temporal and occipital cortices. YFP expression was weaker in occipital and temporal lobes than in frontal and parietal ( Figure 3 , Table 2 ).
In the frontal and parietal cortex, dense bands of YFP-positive, presumed-thalamocortical axons were present throughout the entire frontal lobe and most of parietal lobe including both medial and lateral prefrontal areas, orbitofrontal areas, motor and premotor areas, and primary and secondary somatosensory areas (Figures 3 and 4 , Table 2 ). Examples of YFP-positive fibers are shown in Figure   4 and Figure S3 . There was a notable exception to these observations: in both AT+PT infusion animals, we observed groups of YFP-positive cortical cells in layer II-III in the vicinity of cannula penetration tracts ( Figure   S1C ). This expression is likely due to direct viral infection due to leakage during cannula penetration or withdrawal or due to backflow during CED, and it was not observed in NHP-H.
In the medial plane, moderate to strong YFP expression was observed for all animals across the cingulate cortex and extending to the retrosplenial areas (Figures 3-5 , Figure S2A ).
In the occipital lobe, YFP expression was present in secondary visual areas in all animals, but was absent in the primary visual areas of NHP-A and NHP-B (Table 2 ). However, NHP-H showed regular patches of thalamocortical axonal YFP staining in layer IV of V1. This pattern of expression is consistent with ocular dominance columns originating from P-pathway layer 6 cells of the LGN (arrows in Figure 5B (DLG) and C (V1)).
Expression was also observed in the temporal lobe. Dense bands of layer-specific, thalamocortical YFP expression were seen in the superior temporal lobe of all animals; including the entire insular cortex ( Figure 3 ; panels 3; Figure 4A ), and adjacent auditory areas (also referred as belt and parabelt areas; Hackett and Kaas, 2000; Figure 4A and 5B, Table 2 ). In NHP-H only, there was dense thalamocortical labeling in layers III-IV of the primary (core) auditory cortex including most of rostral (R, RM) and caudal (A1) areas ( Figure 4A and 5B). This observation is consistent with the MGN expression seen in only NHP-H; the other two animals showed little or no YFP expression in primary (A1) core areas ( Figure S2A , Table 2 ).
In the ventral cortical areas, there was a moderate to high density of YFP-positive positive axons in the entorhinal cortex in all animals; the density was higher in NHP-A and NHP-B. All animals showed a highly dense and layer-specific plexus of YFP-positive fibers and many transduced cell bodies in the presubilculum ( Figure 5D , Table 2 ), although hippocampal CA1-3 and dentate areas had little or no YFP-positive axons.
Analysis of tissue damage: There were no large gaps in YFP staining in the thalamus which would indicate large-scale tissue damage associated with CED, although in all cases there were narrow lesions from the cannula penetration (Figure 2A ). Using Nissl staining we observed high level of gliosis along these cannula tracts ( Figure S2B ). 
Acute Physiological Experiment
Surface Illumination Experiment: For NHP-A and NHP-H, we performed epifluorescent imaging at the beginning of the acute electrophysiological experiments. We observed high levels of YFP expression anterior to the central sulcus and little visible expression in the parietal lobe (see Figure 7A for an example). These observations were consistent with the histological findings and raw YFP expression (See Figure S3) presented above.
Electrophysiology with Local Optical Stimulation: In NHP-A and NHP-H, we observed reliable lightevoked increases in firing rates in single unit recordings (see Figure 7C ). These responses were observed at various cortical regions, including sites 5 to 10 mm away from the site of cannula penetration, precluding the possibility that the responses are due to the direct AAV2.2 infection observed around the cannula tract in these animals. In NHP-B, where AAV2.9 was used, we were not able to record any evoked neural responses to light stimulation.
DISCUSSION
This work is aimed at finding efficient techniques for obtaining large-scale optogenetic expression in the primate brain. We demonstrated the feasibility of achieving optogenetic expression across large regions of thalamus and cortex by infusing the optogenetic viral vector in thalamus using MR-guided CED. More importantly we showed the feasibility of achieving large and specific cortical expression due to thalamo-cortical projections. We adopted this approach from previous work by performed by Bankiewicz Lab, which showed that convection enhanced delivery (CED) of AAV viral vectors to thalamus can generate widespread neuronal infection in primate cortex via axonal transport (Kells et al., 2009 ).
We found high concentrations of YFP-positive axons and nearby YFP-positive cell bodies in the frontal cortex. YFP-positive fibers in the cortex appeared to be largely localized to layers III and IV, where the majority of thalamocortical axons are known to innervate (Jacobson and Trojanowski, 1975, Giguere and Goldman-Rakic, 1988) , indicating secretion from the thalamic terminals. In addition, YFP-positive pyramidal neurons were observed in some of the same cortical areas, in layers V/VI.
Such YFP-positive axons and cell bodies were viewed to be the elements of reciprocally projecting pathways, and not as the mere fragments of neighboring cells. This layer specific expression of fibers and cell-bodies enables us to target a specific cortical layer and depending on the scientific question being asked limit the light stimulation to that layer. We interpret the axonal YFP staining in the cortex as anterograde-like transport of YFP, which has post infectiously expressed and filled the entire thalamocortical cell including the axon. Similarly, we interpret distant YFP-positive cell bodies to be a consequence of the virus entering the cell via an axon and being transported into the cell body.
Transduction of neurons that project to the thalamus potentially could occur through incorporation of the AAV vector particle at the axon terminal and intracellular transportation back to the cell body.
Retrograde transport of AAV has been shown to occur in thalamo-cortical axonal projections (Kells et al., 2009 ) and in targeting of motor neurons by intramuscular AAV vector injection (Tuszynski, 2000) .
Retrograde-mediated transduction can explain the ChR2 expression of pyramidal neurons located in layers V and VI since they send their efferent projections to the thalamus (Killackey and Sherman, 2003) .
It is highly likely that the pyramidal cell expression observed in cortex is due to retrograde and anterograde transmission of the virus, and not due to direct infection by virus that diffused into cortex.
This claim is based on several observations. First, MR imaging during infusion showed no evidence of extensive leakage of vector into cortex. This is consistent with previous studies of thalamic and cortical CED showing a linear relationship between the distribution volume and the infusion volume (Lonser et al., 1998 , Lonser et al., 2002 , Krauze et al., 2005 , Szerlip et al., 2007 , Krauze et al., 2008 , Yazdan-Shahmorad et al., 2016 , suggesting a constant rate of convection from the site of infusion.
Second, histological analysis showed no evidence of direct diffusion into the cortex, with the exception of areas immediately adjacent to needle tracks. In many parietal, temporal and occipital areas, we saw no cortical cell expression. In other areas, such as agranular frontal cortex, YFP-positive cell bodies were found only in corticofugal layers V and VI, whereas neighboring intrinsically projecting pyramidal cells in deep layer III remained uninfected.
We were able to record reliable light-evoked activity from single cells in NHP-A and NHP-H. However in NHP-B the light stimulation did not evoke any neural activity despite trying several locations and depths. We performed immunohistochemistry analysis on the tissue from all animals to assess this further. NeuN staining did not show any neuronal toxicity either in the injection site or distal structures.
However, we saw MHC-II upregulation in the injection site of NHP-B where a vector with a neuro-and gliotropic affinity (AAV9, see Table 1 for comparison) was injected. This indicates a clear ongoing immune reaction in NHP-B with mixed cell transduction. Although none of the animals presented any clinical signs throughout the study, this inflammation could have been responsible for our inability to obtain optically-stimulated neural activity in this animal due to downregulation of the transgene.
In previous work, we showed the feasibility of achieving dense (~70-80% of cells) cortical expression across more than 1.3 cm 2 of cortex with only a few cortical CED infusions (Yazdan-Shahmorad et al., 2016 ). Here we show that with one or two thalamic injections we can achieve axonal expression that over a much larger cortical area (almost all of frontal cortex), albeit with a considerably lower density of cell body expression (less than 10%). Because of these differences, the two techniques will likely be used for different applications. Cortical CED is preferable if a high level of neuronal expression is needed over a more limited region of cortex. Thalamic CED would be preferable for studies that require efficient testing of stimulation at many sites across macaque cortex. Furthermore, with thalamic CED, expression is specific to thalamocortical inputs and corticothalamic outputs. Because these are largely localized to different layers (Figure 4) , this technique presents an opportunity for targeting specificity. For example, thalamic CED may be ideal for driving thalamic inputs to sensory cortex, e.g. to evoke more naturalistic patterns of cortical activity for sensory prostheses.
The ability to selectively target thalamocortical inputs is further supported by our post-hoc histological analysis. We only saw expression in visual or auditory cortex when the corresponding thalamic nuclei also showed expression ( Figure 5 ). This suggests that careful targeting of thalamic nuclei would thus be required to achieve precise coverage in a particular cortical area.
The MR-guided CED technique offers several advantages over traditional microinfusions.
Conventional diffusion-based injections of 1-2 μL yield typical regions of expression of about 2-3 mm diameter (Diester et al., 2011 , Jazayeri et al., 2012 , Ruiz et al., 2013 , Lerchner et al., 2014 however they also report a decrement in expression levels by ~1mm from the injection. In contrast, our MRguided CED infusion techniques show vector spread of up to 10 mm diameter from the injection site for cortical CED (Yazdan-Shahmorad et al., 2016) and a full coverage of frontal cortical areas with thalamic CED. Furthermore, CED has been shown to deliver more homogeneous vector densities across the expressing regions (Bobo et al., 1994 , Lieberman et al., 1995 , Lonser et al., 1998 , Szerlip et al., 2007 , Kells et al., 2009 ), compared to conventional diffusion-based injections. We observe large regions with high levels of expressions (Figure 2 ), while traditional injections yield regions of dense expression surrounded by weaker expression (Jazayeri et al., 2012 , Lerchner et al., 2014 . In addition, CED is very much faster than the conventional techniques since it enables infusion of large volumes of vector (up to 200 μl for thalamic delivery) via a single infusion site over 45 minutes. The small number of injections and faster infusion rates make it practical to plan and infuse the viral vector under the guidance of MRI, which enables precise targeting and real time monitoring.
The safety of CED has previously been demonstrated both by histological analyses showing no tissue damage following CED infusions, beyond the cannula tract, and by the lack of post-infusion neurological deficits (Bobo et al., 1994 , Lieberman et al., 1995 , Lonser et al., 1998 , Szerlip et al., 2007 , Kells et al., 2009 . We have also investigated this in detail in our previous paper in which we used CED in primary motor and somatosensory cortices (Yazdan-Shahmorad et al., 2016) . Here we showed gliosis extending 200 μm from the center of the cannula tract in thalamus ( Figure S2B ), but we did not see any histological evidence of tissue damage outside the cannula tract in thalamus and regions of transgene expression.
Unlike our previous studies (Kells et al., 2009 ), here we saw YFP expression in the contralateral thalamus ( Figure S2A ) after AT+PT infusions, though not after MT infusions. This suggests a technical advantage of the single larger volume CED approach. That being said, this outcome may also depend on the position of the injection relative to the internal capsule which strongly laterally isolates the thalamus by the bundles of myelinated fibers; more anterior injections may also push CED material medially toward the contralateral side.
Through this study, we used MR-guided CED injection in thalamus and showed that we can achieve a wide spread of activity across different cortical areas in three NHPs. Furthermore, we showed the feasibility of achieving expression that is limited to a specific cortical area due to thalmo-corticothalamic projections. These results show promise for a practical approach for delivery of optogenetic viral vectors into large cortical and thalamic areas.
Conflict of interest:
PNS has financial interest in Neuralink Corp., a company that is developing clinical therapies using brain stimulation. 
